Yüklüyor......
3′-Phosphoadenosine 5′-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents
Standard treatment for advanced non-small cell lung cancer (NSCLC) with no known driver mutation is platinum-based chemotherapy, which has a response rate of only 30–33%. Through an siRNA screen, 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase 1 (PAPSS1), an enzyme that synthesizes the biologi...
Kaydedildi:
Yayımlandı: | Oncotarget |
---|---|
Asıl Yazarlar: | , , , , , , , , , , , |
Materyal Türü: | Artigo |
Dil: | Inglês |
Baskı/Yayın Bilgisi: |
Impact Journals LLC
2015
|
Konular: | |
Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4627299/ https://ncbi.nlm.nih.gov/pubmed/26220590 |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|